Nivolumab

Definition

Nivolumab is a monoclonal antibody that works as an immune checkpoint inhibitor, specifically targeting the programmed cell death protein 1 (PD-1) receptor. This therapy enhances the immune system's ability to recognize and destroy cancer cells, making it a vital component in the treatment of various malignancies, including melanoma, lung cancer, and kidney cancer.

5 Must Know Facts For Your Next Test

1. Nivolumab was approved by the FDA in 2014 for the treatment of melanoma and has since been approved for other cancers as well.
2. The drug is administered via intravenous infusion, typically every two weeks, depending on the specific cancer type being treated.
3. Common side effects of nivolumab include fatigue, rash, and diarrhea, but it can also lead to immune-related adverse effects affecting various organs.
4. Nivolumab has shown significant improvement in overall survival rates for patients with certain types of advanced cancers compared to traditional chemotherapy.
5. Clinical trials have demonstrated that nivolumab can lead to durable responses in some patients, meaning that benefits can persist long after treatment has ended.

Review Questions

• How does nivolumab enhance the body's immune response against cancer cells?
  • Nivolumab enhances the body's immune response by blocking the PD-1 receptor on T-cells. This blockade prevents cancer cells from evading immune detection by allowing T-cells to remain active and effectively target tumor cells. By inhibiting this checkpoint, nivolumab enables the immune system to better recognize and attack cancer, improving patient outcomes.
• Compare the mechanisms of action between nivolumab and traditional chemotherapy treatments.
  • Nivolumab works by specifically targeting and inhibiting PD-1 to enhance T-cell activity against tumors, which is fundamentally different from traditional chemotherapy that primarily targets rapidly dividing cells. While chemotherapy can damage both healthy and cancerous cells indiscriminately, nivolumab leverages the body's own immune system to selectively attack cancer cells, often resulting in fewer systemic side effects and potentially more effective long-term responses.
• Evaluate the impact of nivolumab on survival rates in patients with advanced melanoma compared to conventional therapies.
  • Nivolumab has significantly impacted survival rates in patients with advanced melanoma by providing more durable responses than conventional therapies. Studies have shown that patients treated with nivolumab experience longer overall survival compared to those receiving standard chemotherapy or other treatments. This advancement highlights the shift towards immunotherapy in oncology and emphasizes the importance of targeted therapies that improve patient quality of life while offering substantial clinical benefits.

Related terms

Checkpoint Inhibitors: A class of drugs that block proteins on immune cells or cancer cells that prevent the immune system from attacking cancer, thus enhancing the immune response against tumors.

Immunotherapy:

A treatment approach that utilizes the body's own immune system to fight cancer by stimulating or enhancing immune responses.

Programmed Cell Death Protein 1 (PD-1): A protein on the surface of T-cells that, when bound by its ligands, inhibits T-cell activation and reduces the immune response against cancer cells.